What is Accumetrics?
Accumetrics operates as a specialized medical technology firm dedicated to the advancement of platelet function assessment. Its flagship offering, the VerifyNow System, represents a significant leap in diagnostic efficiency, providing clinicians with rapid, actionable data regarding a patient's response to various antiplatelet agents. By addressing critical therapeutic categories—including aspirin, P2Y12 inhibitors, and GP IIb/IIIa inhibitors—the company bridges a vital gap in cardiovascular care. The platform is engineered for ease of use, allowing for real-time clinical decision-making that directly impacts patient safety and treatment efficacy. Through its commitment to rigorous diagnostic standards, Accumetrics has established itself as an essential partner for healthcare providers managing complex antiplatelet regimens.
How much funding has Accumetrics raised?
Accumetrics has raised a total of $6M across 1 funding round:
Private Equity
$6M
Private Equity (2013): $6M with participation from Essex Woodlands Health Ventures, RiverVest Venture Partners, LLC, and SightLine Partners, LLC
Key Investors in Accumetrics
Essex Woodlands Health Ventures
EW Healthcare Partners is a healthcare growth equity firm that invests in companies across the US and Europe, focusing on driving positive change in healthcare while achieving high returns.
RiverVest Venture Partners, LLC
RiverVest is a prominent venture capital firm focused on building life science companies to meet significant unmet medical needs through science, strategy, and innovation.
SightLine Partners, LLC
SightLine Partners is an investment firm that provides strategic capital and support to companies within the healthcare and life sciences sectors.
What's next for Accumetrics?
With the recent influx of capital, Accumetrics is well-positioned to accelerate its market penetration and expand its diagnostic portfolio. The strategic focus will likely center on enhancing the accessibility of the VerifyNow System across global clinical settings, thereby standardizing the approach to antiplatelet therapy management. Future growth initiatives are expected to leverage this financial runway to support ongoing research and development, ensuring that the company remains responsive to the evolving needs of the medical community. By maintaining its focus on high-impact diagnostic tools, Accumetrics is poised to capture a larger share of the cardiovascular diagnostics market while continuing to drive improvements in patient-centric care models.
See full Accumetrics company page
